151 related articles for article (PubMed ID: 33790161)
1. [Clinical Application of Gemcitabine plus Cisplatin plus Bevacizumab Combination Chemotherapy for Ovarian Clear Cell Carcinoma].
Nakagawa M; Ito K; Uragami K; Suzuki J; Shiomi M; Ono H; Shimoji K; Yamashita M; Onoue M; Yoshioka E; Goto M; Tashima L; Hori K
Gan To Kagaku Ryoho; 2021 Mar; 48(3):375-378. PubMed ID: 33790161
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma.
Kose MF; Sufliarsky J; Beslija S; Saip P; Tulunay G; Krejcy K; Minarik T; Fitzthum E; Hayden A; Melemed A
Gynecol Oncol; 2005 Feb; 96(2):374-80. PubMed ID: 15661224
[TBL] [Abstract][Full Text] [Related]
3. Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer.
Richardson DL; Backes FJ; Seamon LG; Zanagnolo V; O'Malley DM; Cohn DE; Fowler JM; Copeland LJ
Gynecol Oncol; 2008 Dec; 111(3):461-6. PubMed ID: 18829088
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer.
Eisenhauer EL; Zanagnolo V; Cohn DE; Salani R; O'Malley DM; Sutton G; Callahan MJ; Cobb B; Fowler JM; Copeland LJ
Gynecol Oncol; 2014 Aug; 134(2):262-6. PubMed ID: 24910452
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of gemcitabine, cisplatin, and bevacizumab for first recurrent and refractory ovarian clear cell carcinoma Kansai Clinical Oncology Group-G1601.
Ito K; Nakagawa M; Shimokawa M; Hori K; Tashima L; Goto M; Yanagida S; Suzuki J; Kaya R; Kawabata A; Yamada K; Park J; Nasu H; Nishio S; Kondo E; Kaneda M; Tsubamoto H; Arakawa A; Nagasawa T; Motohashi T
Anticancer Drugs; 2023 Aug; 34(7):857-865. PubMed ID: 36729915
[TBL] [Abstract][Full Text] [Related]
6. The safety and efficacy of cisplatin plus gemcitabine in recurrent ovarian cancer.
Tomita Y; Saito T; Okadome M; Eto T; Ariyoshi K; Shimamoto K
Int J Clin Oncol; 2014 Aug; 19(4):662-6. PubMed ID: 23887730
[TBL] [Abstract][Full Text] [Related]
7. Platinum rechallenge treatment using gemcitabine plus carboplatin with or without bevacizumab for platinum-resistant ovarian cancer.
Nasu H; Nishio S; Park J; Yoshimitsu T; Matsukuma K; Tasaki K; Katsuda T; Terada A; Tsuda N; Ushijima K
Int J Clin Oncol; 2022 Apr; 27(4):790-801. PubMed ID: 34985551
[TBL] [Abstract][Full Text] [Related]
8. Complete remission of recurrent and refractory ovarian cancers using weekly administration of bevacizumab and gemcitabine/oxaliplatin: report of two cases.
Takano M; Ikeda Y; Kudoh K; Kita T; Sasaki N; Kikuchi Y
Eur J Gynaecol Oncol; 2013; 34(1):90-3. PubMed ID: 23590010
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Nagao S; Kogiku A; Suzuki K; Shibutani T; Yamamoto K; Jimi T; Kitai M; Shiozaki T; Matsuoka K; Yamaguchi S
J Ovarian Res; 2020 Feb; 13(1):14. PubMed ID: 32028974
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer J; Shannon CM; Baumann K; Rau J; Harter P; Joly F; Sehouli J; Canzler U; Schmalfeldt B; Dean AP; Hein A; Zeimet AG; Hanker LC; Petit T; Marmé F; El-Balat A; Glasspool R; de Gregorio N; Mahner S; Meniawy TM; Park-Simon TW; Mouret-Reynier MA; Costan C; Meier W; Reinthaller A; Goh JC; L'Haridon T; Baron Hay S; Kommoss S; du Bois A; Kurtz JE;
Lancet Oncol; 2020 May; 21(5):699-709. PubMed ID: 32305099
[TBL] [Abstract][Full Text] [Related]
11. Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma.
Villella J; Marchetti D; Odunsi K; Rodabaugh K; Driscoll DL; Lele S
Gynecol Oncol; 2004 Dec; 95(3):539-45. PubMed ID: 15581960
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group.
Brewer CA; Blessing JA; Nagourney RA; Morgan M; Hanjani P
Gynecol Oncol; 2006 Nov; 103(2):446-50. PubMed ID: 16643994
[TBL] [Abstract][Full Text] [Related]
13. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
[TBL] [Abstract][Full Text] [Related]
14. Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis.
Takasaki K; Miyamoto M; Takano M; Soyama H; Aoyama T; Matsuura H; Kato K; Sakamoto T; Kuwahara M; Iwahashi H; Ishibashi H; Yoshikawa T; Furuya K
Cancer Chemother Pharmacol; 2018 May; 81(5):809-814. PubMed ID: 29500481
[TBL] [Abstract][Full Text] [Related]
15. [Gemcitabine based combination chemotherapy, a new salvage regimen for recurrent platinum resistant epithelial ovarian cancer].
Chu P; Lu CH; Sheng XG; Zhou CX; Li DP; DU XL; Liu NF
Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):808-12. PubMed ID: 21211276
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of intravenous gemcitabine and an intraperitoneal platinum agent in the treatment of ovarian cancer.
Giuntoli RL; Bristow RE; Diaz-Montes TP; Armstrong DK
J Chemother; 2011 Jun; 23(3):163-7. PubMed ID: 21742586
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202).
Miyanaga A; Kubota K; Hosomi Y; Okuma Y; Minato K; Fujimoto S; Okamoto H; Satouchi M; Isobe H; Aono H; Takiguchi Y; Gemma A;
Jpn J Clin Oncol; 2019 Aug; 49(8):749-754. PubMed ID: 31070750
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine-cisplatin: a schedule finding study.
Kroep JR; Peters GJ; van Moorsel CJ; Catik A; Vermorken JB; Pinedo HM; van Groeningen CJ
Ann Oncol; 1999 Dec; 10(12):1503-10. PubMed ID: 10643544
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy.
Sehouli J; Stengel D; Oskay G; Camara O; Hindenburg HJ; Klare P; Blohmer J; Heinrich G; Elling D; Ledwon P; Lichtenegger W;
Ann Oncol; 2002 Nov; 13(11):1749-55. PubMed ID: 12419747
[TBL] [Abstract][Full Text] [Related]
20. Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
Kim SI; Lee EJ; Lee M; Chung H; Kim JW; Park NH; Song YS; Kim HS
Int J Gynecol Cancer; 2020 Dec; 30(12):1943-1950. PubMed ID: 33055266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
